{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:42:37Z","timestamp":1775947357313,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013410","name":"LivaNova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Research Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000942","name":"Brain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.yebeh.2022.108729","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T05:34:38Z","timestamp":1653370478000},"page":"108729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitis"],"prefix":"10.1016","volume":"132","author":[{"given":"Robb","family":"Wesselingh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tarlinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Seneviratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Kyndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Stankovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassie","family":"Nesbitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendyl","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Macdonell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence J.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108729_b0005","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.yebeh.2018.10.038","article-title":"Seizure characteristics, treatment, and outcome in autoimmune synaptic encephalitis: A long-term study","volume":"94","author":"Zhang","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108729_b0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jns.2018.10.026","article-title":"Factors underlying the development of chronic temporal lobe epilepsy in autoimmune encephalitis","volume":"396","author":"Casciato","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108729_b0015","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3389\/fneur.2018.01136","article-title":"Characteristics of seizure and antiepileptic drug utilization in outpatients with autoimmune encephalitis","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108729_b0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/epi.12879","article-title":"Postencephalitic epilepsy: clinical characteristics and predictors","volume":"56","author":"Singh","year":"2015","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108729_b0025","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.clinph.2016.07.014","article-title":"Etiological associations and outcome predictors of acute electroencephalography in childhood encephalitis","volume":"127","author":"Mohammad","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2022.108729_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108571","article-title":"Electroclinical biomarkers of autoimmune encephalitis","volume":"128","author":"Wesselingh","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108729_b0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108729_b0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108729_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNP.0b013e3182784729","article-title":"American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2012 version","volume":"30","author":"Hirsch","year":"2013","journal-title":"J Clin Neurophysiol"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108729_b0050","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/epi.12653","article-title":"Critical Care EEGMRC. Interrater agreement for Critical Care EEG Terminology","volume":"55","author":"Gaspard","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108729_b0055","series-title":"Frontiers in econometrics","article-title":"Conditional logit analysis of qualitative choice behavior","author":"McFadden","year":"1974"},{"key":"10.1016\/j.yebeh.2022.108729_b0060","first-page":"189","article-title":"Boostrap confidence intervals","author":"DiCiccio","year":"1996","journal-title":"Stat Sci"},{"key":"10.1016\/j.yebeh.2022.108729_b0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108729_b0070","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108729_b0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.25655","article-title":"Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1\/CASPR2 epilepsy","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"issue":"5-6","key":"10.1016\/j.yebeh.2022.108729_b0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000490900","article-title":"Early predictors of drug-resistant epilepsy development after convulsive status epilepticus","volume":"79","author":"Yuan","year":"2018","journal-title":"Eur Neurol"},{"key":"10.1016\/j.yebeh.2022.108729_b0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fneur.2018.00181","article-title":"Evaluation of microglial activation in multiple sclerosis patients using positron emission tomography","volume":"9","author":"Airas","year":"2018","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108729_b0090","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/epi.16515","article-title":"Seizures in autoimmune encephalitis: Kindling the fire","volume":"61","author":"Wesselingh","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108729_b0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","article-title":"Neurological autoantibody prevalence in epilepsy of unknown etiology","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:47:55Z","timestamp":1761504475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022001780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":19,"alternative-id":["S1525505022001780"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108729","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108729"}}